行情

RIGL

RIGL

里格尔制药
NASDAQ

实时行情|Nasdaq Last Sale

4.460
+2.300
+106.48%
交易中 12:52 07/14 EDT
开盘
3.210
昨收
2.160
最高
5.24
最低
3.160
成交量
1.36亿
成交额
--
52周最高
5.24
52周最低
1.230
市值
7.52亿
市盈率(TTM)
-26.4846
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测RIGL价格均价为7.17,最高价位8.00,最低价为5.00。

EPS

RIGL 新闻

更多
Mid-Day Market Update: Dow Rises 1%; Rigel Pharmaceuticals Shares Spike Higher
Midway through trading Tuesday, the Dow traded up 1.03% to 26,354.06 while the NASDAQ fell 0.37% to 10352.46. The S&P also rose, gaining 0.34% to 3,166.08.
Benzinga · 41分钟前
Mid-Morning Market Update: Markets Mostly Lower; JPMorgan Tops Q2 Views
Following the market opening Tuesday, the Dow traded up 0.15% to 26123.80 while the NASDAQ fell 1.74% to 10210.48. The S&P also fell, dropping 0.55% to 3,137.81.
Benzinga · 1小时前
Benzinga Pro's Top 5 Stocks To Watch For Tues., Jul. 14, 2020: KBE, NFLX, RIGL, JNJ, CIDM
Today's 5 Stock Ideas:  SPDR S&P Bank ETF (KBE) - This ETF will see heavier-than-normal interest Tuesday amid earnings out of JP Morgan (JPM), Citigroup (C) and Wells Fargo
Benzinga · 4小时前
80 Biggest Movers From Yesterday
Gainers Equillium, Inc. (NASDAQ: EQ) shares surged 730.7% to close at $26.50 on Monday after the company disclosed that Itolizumab significantly reduced mortality in coronavirus patients, according to a clinical trial conducted in India by its partner Biocon.
Benzinga · 7小时前
Annexon Initiates $100 Million IPO Effort
Seeking Alpha - Article · 3天前
Rigel Announces Availability of TAVLESSE® (Fostamatinib Disodium Hexahydrate) in Europe
PR Newswire · 5天前
Rigel Announces Availability Of TAVLESSE In Europe
TAVLESSE initial launch in Germany and the U.K. by Grifols S.A. SOUTH SAN FRANCISCO, Calif., July 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that Grifols S.A., its
Benzinga · 5天前
Is Rigel Pharmaceuticals, Inc. (RIGL) Going to Burn These Hedge Funds?
Insider Monkey · 06/28 02:29

所属板块

生物技术和医学研究
+0.95%
制药与医学研究
+0.66%

热门股票

代码
价格
涨跌幅

RIGL 简况

Rigel Pharmaceuticals, Inc.是一家临床阶段的生物技术公司。该公司从事改善免疫和血液疾病、癌症和罕见疾病患者生活的新型小分子药物的发现、开发和供应业务。该公司的研究重点是对疾病机制至关重要的信号通路。该公司的产品包括TAVALISSE,是一种口服脾酪氨酸激酶(SYK)抑制剂,用于治疗成人慢性免疫性血小板减少症(ITP)患者。其目前的临床计划包括fostamatinib在自身免疫性溶血性贫血和IgA肾病中的2期研究,以及针对其白细胞介素受体相关激酶(IRAK)计划的1期研究。此外,它还与合作伙伴BerGenBio AS、Daiichi Sankyo和Aclaris Therapeutics合作开发候选产品。
展开

微牛提供Rigel Pharmaceuticals, Inc.(NASDAQ-RIGL)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的RIGL股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易RIGL股票基本功能。